약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1.

A 2x2 table for disproportionality calculation

Adverse events of interest All other adverse events
baricitinib (or tocilizumab) A B
Comparison group C D
Yakhak Hoeji 2022;66:49-57 https://doi.org/10.17480/psk.2022.66.2.49
© 2022 Yakhak Hoeji